Milvexian in secondary stroke prevention

“Despite major advances in cardiovascular and stroke treatment over the past two decades, millions of patients currently remain untreated or undertreated due to the risk of bleeding, but for whom thrombotic events could be prevented,” said Robert Harrington, MD, Arthur L. Bloomfield. Professor of Medicine and Chairman of the Department of Medicine, Stanford University, Librexia.i […]

Rate this: